The Centre for Translational Pathology at the University of Melbourne provides NATA - accredited diagnostic laboratory support for clinical studies and clinical trials exploring the clinical validity, utility and cost effectiveness of predictive, prognostic and pharmacodynamic biomarkers for patients with cancer. The Centre is technology agnostic and supports a range of platforms including immunohistochemistry, in situ hybridisation, digital image analysis, Sanger sequencing, and next generation sequencing including targeted panels and exome analysis.
he Centre for Translational Pathology at the University of Melbourne and the Molecular Pathology laboratory at the Peter MacCallum Cancer Centre will form partnership in 2016 when they co-locate to the new Victorian Comprehensive Cancer Centre. Both facilities have received investments through the Translating Health Discovery project to establish state-of-the art molecular pathology services using the latest next generation sequencing technologies.
The Centre is accredited by NATA for medical testing under category S for immunohistochemistry and in situ hybridisation, DNA sequencing for germline somatic (mosaic) mutations, and next generation sequencing including targeted gene panel. The laboratory is certified as ISO 15189:2012.
Year of establishment
Access and pricing
Please get in touch to discuss your requirements.
Ventana Medical Systems - BRAF IHC
Merck - ICECREAM trial
Australasian Gastro-Intestinal Trials Group - TACTIC trial
VCCC - ALLOCATE project
Contact: Paul Waring
Phone: +61 (0)3 8344 5849
||BRAK, ALK1, ROS1, MMR, CYCLIN E1, MET
|In situ hybridisation
||HER2, CCNE1, MET
||BRAF, NRAS, PIK3CA, EGFR, LIT, PDGFRA
Next generation sequencing (HiSeq 2500, MiSeq)
Colon, lung, AML, ovarian panels